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Abstract 
 
Objective: To assess the diagnostic accuracy of placental alpha- microglobulin-1 (PAMG-1), 
fetal fibronectin (fFN), and phosphorylated insulin-like growth factor-binding protein-1 
(phIGFBP-1) tests in the prediction of spontaneous preterm birth in women with symptoms 
of preterm labor within 7 days (sPTB≤7d) of testing using formal methods for systematic 
This article is protected by copyright. All rights reserved.
 
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this 
article as doi: 10.1002/uog.19119
  
A
cc
ep
te
d 
A
rti
cl
e
review. Further analysis looking into performance in low, intermediate and high-risk patient 
groups.  
Methods: Two reviewers independently searched the Cochrane, MEDLINE, PubMed and 
ResearchGate bibliographic databases. The search was done from inception- October 2017. 
Cohort studies that reported on the predictive accuracy of PAMG- 1, fFN, and phIGFBP-1 
for the prediction of sPTB in women with symptoms of preterm labor within 7 days of testing 
were included. Summary ROC curve, SN, SP, PPV, NPV and LRs were generated using 
indirect methods for the calculation of pooled effect sizes with a bivariate linear mixed model 
for the logit of sensitivity and specificity, with each diagnostic test as a covariate described 
by Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. 
 
Results: Bivariate mixed model pooled sensitivities (SN) for PAMG-1, fFN and phIGFBP-1 
for sPTB≤7d were 76% (95% CI, 0.57-0.89), 58% (95% CI, 0.47-0.68), and 93% (95% CI, 
0.88-0.96). Bivariate mixed model pooled specificities (SP) were 97% (95% CI, 0.95-0.98), 
84% (95% CI, 0.81-0.87), and 76% (95% CI, 0.70-0.80). Bivariate mixed model pooled 
positive predictive values (PPV) for PAMG-1, fFN, and phIGFBP-1 for sPTB≤7d were 
76.3% (95% CI, 0.69-0.84) [p<0.05], 34.1% (95% CI, 0.29-0.39), and 35.2% (95% CI, 0.31-
0.40). Bivariate mixed model pooled negative predictive values (NPV) were 96.6% (95% CI, 
0.94-0.99), 93.3% (95% CI, 0.92-0.95), and 98.7% (95% CI, 0.98-0.99). Bivariate mixed 
model pooled positive likelihood ratio (LR+) for PAMG-1, fFN, and phIGFBP-1 for 
sPTB≤7d were 22.51 (15.09-33.60) [p<0.05], 3.63 (2.93-4.50), and 3.80 (3.11-4.66). 
Bivariate mixed model pooled negative likelihood ratio (LR–) for PAMG-1, fFN, and 
phIGFBP-1 for sPTB≤7d were 0.24 (0.12-0.48) [p<0.05], 0.50 (0.39-0.64), and 0.09 (0.05-
0.16). Area under the curve (AUC) for PAMG-1, fFN, and phIGFBP-1 for sPTB≤7d were 
0.961, 0.874, and 0.801. 
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Conclusions: It is well understood that prevalence affects a diagnostic test’s predictive 
performance, and that in lower-prevalence syndromes such as sPTB, using highly specific 
assays may optimize management. Our study confirms that the PAMG-1 test was found to 
have the highest PPV and LR+ across all risk stratification groups with statistical 
significance while the NPV and LR– remained similarly high across all three biomarkers. 
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Introduction 
Accurate diagnosis of preterm birth (PTB) is a vexing challenge. PTB, and its complications, 
are the leading causes for neonatal morbidity and mortality; and are associated with the most 
common and costly obstetrical indications for hospital admissions.1-4   Preterm labor (PTL) 
hospitalizations account for nearly 33% of all in-patient prenatal unit admissions, up to 85% 
of which do not deliver within the next 7 days.5,6 This results in unnecessary and potentially 
harmful treatments including corticosteroids and tocolytics.7-9 
Approximately 65-75% of PTB are spontaneous, while the remaining are iatrogenic.10 
Spontaneous PTB may be caused by multiple pathological processes;11,12 thus, prediction of 
PTB has been a long-standing challenge, as clinical symptoms alone are not of adequate 
predictive accuracy.13,14 The most notable methods for PTB prediction are cervical length 
(CL) measurement and biomarker tests based on fetal fibronectin (fFN), phosphorylated 
insulin-like growth factor-binding protein-1 (phIGFBP-1), or placental alpha-microglobulin-
1 (PAMG-1).  
All three biomarkers were evaluated in multiple clinical settings and their performance 
showed considerable variation between studies, based on demographic and other factors 
underlying each cohort, such as the prevalence, ranging from 0.9%15 to 52%,16 of 
spontaneous PTB within 7 days of testing (sPTB≤7d).  Concomitantly, the predictive values 
associated with each biomarker also varied. Positive predictive values (PPV) for PAMG-1, 
fFN, and phIGFBP-1, were 23.1%-100%,15,17 4.3-92.3%,15,18 2.2-81.3%.18,19 Negative 
predictive values (NPV) for PAMG-1, fFN, and phIGFBP-1 were 93.0-100%,20,21 73.2-
100%,18,22 and 61.8- 98.4%.16,19 The range of predictive values presents a challenge to 
clinicians evaluating biomarker tests for their population, which may have a different pre-
test probability of sPTB≤7d than that reported by any one study. While the impact of 
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disease prevalence on the performance of a diagnostic test is well-established,23 it has not 
yet been considered. 
 
This review has two objectives. First, to perform the most up-to-date systematic review and 
meta-analysis of the PAMG-1, fFN and phIGFBP-1 biomarkers for the prediction of 
sPTB≤7d in symptomatic women using methods described in the Cochrane Handbook for 
Systematic Reviews of Diagnostic Test Accuracy. Second, to stratify each biomarker’s test 
performance by the pretest probabilities of sPTB≤7d, associated with various cervical 
length measurement ranges, in PTL symptomatic women and who have clinically intact 
membranes and minimal cervical dilation (≤ 3 cm). 
 
Methods and Materials 
This study followed a prospective review protocol and is reported in accordance with 
recommended methods for systematic reviews of diagnostic test accuracy using the PRISMA 
Guidelines.24,25 
Literature Review 
The literature search was performed for PAMG-1, fFN, and phIGFBP-1 for test performance 
for the prediction of preterm birth in women with symptoms of preterm labor. The search 
was conducted from inception up to October 2017. Two reviewers independently searched 
the Cochrane, MEDLINE, PubMed and ResearchGate bibliographic databases using a 
combination of keywords, including “PartoSure”, “PAMG-1”; “fetal fibronectin”, “ffn”, 
“fibronectin”, “Rapid fFN”, or “QuikChek”; “ActimPartus” or “phIGFBP-1”. Additional 
citations were identified by reviewing the proceedings and submitted abstracts of multiple 
international meetings and conferences focused on maternal-fetal medicine or preterm birth. 
All references in the retrieved articles were screened for further studies relevant to the 
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objective of this review. Editorials and reviews, although themselves not included in the 
analysis, were also scanned for relevant studies. 
 
Only prospective or cohort studies that met the following criteria were included in this 
analysis: (a) clinical study objective was to determine accuracy of specified biomarkers for 
prediction of preterm birth (b) reported or included sufficient information to calculate test 
performance metrics for the prediction of spontaneous preterm birth within 7 days of testing 
(i.e. the reference standard); (c) the study population had signs or symptoms suggestive of 
preterm labor, clinically intact membranes and minimal cervical dilatation (≤ 3 cm); and (d) 
the study population included patients <37 weeks gestation. Studies were excluded if they 
had any of the following characteristics: (a) clinical study objective was not to determine 
accuracy of specified biomarkers for prediction of preterm birth (b) the performance metrics 
for the prediction of preterm birth within 7 days of testing were either not reported or could 
not be calculated through the information provided; (c) the test studied either is not currently 
available commercially or was evaluated using a test procedure not recommended by the 
respective manufacturer; (d) was a reply or review article with no original data provided; or 
(e) reported duplicate performance metrics already reported by an earlier study. When in 
doubt, study authors were contacted to ensure that there was no overlap between study data.  
 
Data Extraction 
Information was extracted independently for each primary study using a specifically 
designed data collection form to capture the study characteristics (i.e. authors, setting, year of 
publication, year of recruitment, method of recruitment, prospective or retrospective data 
collection, percentage of women recruited included in the analysis); patient population 
characteristics (i.e. sample size, prevalence of birth within 7 days, and demographic 
information); inclusion and exclusion criteria (i.e. gestational age at sampling, singleton or 
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multiple gestations, cervical dilation, status of fetal membranes, presence of vaginal 
bleeding, intercourse in the past 24 hours, contraction frequency, cervical length); preterm 
birth endpoint used for test performance calculations; and numbers of true-positive, false-
positive, true-negative, and false-negative test results for the prediction of spontaneous 
preterm birth within 7 days of testing. The studies with insufficient information, were 
excluded from the meta-analysis. 
 
Assessment the Risk of Bias 
Study quality was assessed using a modified version of the Quality Assessment of Diagnostic 
Accuracy Studies-2 (QUADAS-2) tool.26 All the included studies were judged as ‘low risk’, 
‘high risk’, or ‘unclear risk’ of bias and were evaluated and interpreted in consideration of 
the following characteristics: 
a. Patient selection. Patients who were recruited consecutively or randomly were considered to 
have low risk of bias. Studies that used convenience sampling, arbitrary recruitment, or 
nonconsecutive recruitment were considered to have a high risk of bias. 
b. Reference standard. Studies that had at least one of their endpoints defined as spontaneous 
preterm birth within 7 days of testing were considered to have a low risk of bias. Studies that 
included only endpoints defined as either preterm birth, inclusive of iatrogenic preterm 
deliveries, or medically-indicated preterm birth alone within 7 days of testing, were 
considered to have a high risk of bias.  
c. Blinding. Studies clearly stating that clinicians managing patient care did not have 
knowledge of biomarker test results were considered to have a low risk of bias. Studies 
where the managing clinicians had knowledge of biomarker test results were considered to 
have a high risk of bias. 
d. Inclusion of patients in the analysis. Studies that included ≥85% of recruited patients into 
the calculations of test performance were considered to have a low risk of bias. Studies that 
included <85% of recruited patients into the calculations of test performance were 
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considered to have a high risk of bias. 
A summary score was not calculated to estimate the overall quality of each study, as 
interpretation of such summary scores may be potentially misleading.27 
 
Data Synthesis 
Data from individual studies was synthesized for singleton gestations when possible. All 
studies that met inclusion criteria were stratified according to three pre-defined, clinically-
relevant risk classifications based on the pre-test probability of sPTB≤7d. The three pre-
defined groups were Low [Risk], Intermediate [Risk], and High [Risk]. The probability of 
sPTB≤7d in patients with cervical length measurements between 15 and 30 mm was used as 
the reference for the Intermediate group. Three studies were selected as reference, as they 
were the largest studies to date incorporating the use of a biomarker test along with cervical 
length measurements. The sPTB≤7d in this group of patients with cervical length 
measurements between 15 and 30 mm was 7.5%-10.7% (95% CI 4.58%-16.25%). 28-30 The 
Low Risk group was classified by rates of sPTB≤7d below the lower bound of the 95% CI of 
that range (i.e. those studies with a pre-test probability of sPTB≤7d less than 4.58%).28 The 
Intermediate Risk group was classified by rates of sPTB≤7d within the 95% CI of that range, 
(i.e. those studies with a pre-test probability of sPTB≤7d between 4.58% and 16.25%).28-30 
The High Risk group was classified by rates of sPTB≤7d above the upper bound of the 95% 
CI of that range (i.e. those studies with a pre-test probability of sPTB≤7d greater than 
16.25%).30  
 
Statistical Analysis Comparing PAMG-1, fetal fibronectin, and phIGFBP-1 
Data extracted from each study were arranged in 2x2 contingency tables. Pooled estimates 
were obtained for each risk classification group using a bivariate linear mixed model for the 
logit of sensitivity and specificity, with each diagnostic test as a covariate described by 
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Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy.31 As evaluation of 
the performance of the three diagnostic tests was a central aim of this meta-analysis, analysis 
was also performed with the bivariate linear mixed effects model with type of test as a 
covariate to assess difference in test accuracy measures.31 Pooled estimates are reported from 
this same model for formal statistical comparison. The bivariate mixed model accounted for 
differences in study sample sizes as well as both within and between study variability, while 
also accounting for correlation between the sensitivity and the specificity. Models were fit in 
SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) using PROC NLMIXED as described 
in the METADAS SAS macro.32-37 Model convergence could not be attained in the Low and 
Intermediate risk groups; therefore the model was simplified to include random study effect 
only without random effects for sensitivity and specificity by study, thereby removing 
estimate of correlation between sensitivity and specificity from the model. Sensitivity and 
specificity with 95% CIs were calculated as estimated from the bivariate models with the 
differences between diagnostics tests evaluated on the logit scale. The likelihood ratios were 
estimated thereafter from the pooled sensitivities and specificities for each biomarker test 
with 95% CIs with differences evaluated on the log scale. Similarly, the NPVs and PPVs for 
each risk classification group were calculated using the pooled estimates of sensitivity and 
specificity. Standard errors and confidence intervals were estimated based on the delta 
method with normal approximation. Global tests based on the F-statistics were performed to 
assess the difference in the outcomes among the three biomarker tests by each risk 
classification group. Pairwise comparisons were evaluated from the model with a t-statistic 
and all the p-values were two-sided. All the p-values presented were nominal with no 
adjustment for the test multiplicity with statistical significance set as p<0.05.  
 
The summary receiver-operating characteristic (ROC) curve was estimated according to the 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
method of Rutter and Gatsonis (2001) as also described by Arends (2008).38,39 The area under 
the curve (AUC) was computed using the R package meta4diag (The R Foundation, Vienna, 
Austria) assuming the SROC curve is that of Rutter and Gatsonis. 
Results 
Study Selection 
The process of identification and selection of studies is summarized in Figure 1. The 
database search identified 2239 citations. From the identified citations, 2020 studies were 
excluded based on irrelevant titles and duplicates. The full text articles of the remaining 
citations were reviewed and further 253 studies were excluded for the following reasons:  
clinical study objective was not to determine accuracy of specified biomarkers for prediction 
of preterm birth (253), different reference standard (84), not original data (reply/review) (38), 
duplicate results (24) and other (7). The characteristics of studies included in the systematic 
review are summarized in Table 1. 
 
Study Characteristics and Risk of Bias 
Figure 2 summarizes the quality assessment of the studies included. Seven studies (11%) 
fulfilled all four of the quality criteria; 23 studies (35%) fulfilled three quality criteria. The 
remaining 36 studies (55%) fulfilled two or less quality criteria, suggesting potential 
methodological flaws.  
 
Overall, there were 14 PAMG-1 studies (n=2278),15,17,20,21,30,40-48 40 fFN studies 
(n=7431),14,15,18,20,22,28,29,40-42,49-78 and 22 phIGFBP-1 studies (n=3192)16,18,19,28,30,48,54,73,79-92 were 
included in our final analysis. Of these, 10 studies included performance metrics for more 
than one biomarker. The studies enrolled patients at centers from different regions of the 
world, with the highest proportion from Europe (39%), second highest from North America 
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(21%), followed by Asia (15%), Middle East (14%), Latin America (5%), Oceania (5%) and 
Africa (2%). The sample sizes ranged from 2277 to 72552 subjects (mean, 170). 
 
Prediction of spontaneous preterm birth within 7 days of testing 
Figure 3 shows the sensitivity and specificity of all three biomarker tests in the individual 
studies to predict preterm birth within 7 days in symptomatic women. For Low Risk Group, 
three studies (n=1074)15,40,43 met the criteria for PAMG-1, eight studies (n=2667)15,22,40,49,52-55 
met the criterial for fFN, and two studies (n=559)19,54 for phIGFBP-1. For the Intermediate 
Risk Group, nine studies (n=929)17,21,30,41,44-48 met the criteria for PAMG-1, 25 
(n=3714)14,29,41,50,51,56-75 met the criterial for fFN, and eight studies (n=1108)30,48,73,79-83 for 
phIGFBP-1. For the High Risk Group, two studies (n=275)20,42 met the criteria for PAMG-1, 
seven (n=1050)18,20,28,42,76-78 met the criterial for fFN, and twelve studies (n=1525)16,18,28,84-92 
for phIGFBP-1.  Table 2 shows the pooled summary sensitivity and specificity results, as 
well as per risk group for each biomarker test with their 95% CIs from the bivariate mixed 
model, with each diagnostic test as a covariate. Table 3 shows the PPV, NPV, LR+ and LR- 
that were estimated with the bivariate mixed model from the sensitivities and specificities for 
each biomarker test with their 95% CIs for each risk classification group. PAMG-1 had a 
statistically superior PPV (p<0.05) across all three risk classification groups, demonstrating a 
2-to-6 fold higher PPV than those of fFN and phIGFBP-1. Furthermore, the pairwise 
comparisons of the NPV between tests did not show a statistically-significant difference. 
 
As the clinical usefulness of a diagnostic test may be largely determined by the accuracy with 
which it identifies its target disorder, this accuracy is best determined by assessing the 
likelihood ratios.52 An LR+ above 10 and an LR- below 0.1 are considered to provide strong 
predictive evidence in most circumstances. Moderate prediction can be achieved with LR+ 
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and LR- values of 5-10 and 0.1-0.2, respectively, whereas those less than 5 and greater than 
0.2 give only minimal prediction.93 As with the predictive values, the positive likelihood 
ratios show a similar trend with PAMG-1 having a statistically superior LR+ (p<0.05) across 
all risk classification groups, as compared to fFN and phIGFBP-1. The PAMG-1 test is the 
only biomarker to have a LR+ above 10 in all the three risk classification groups, indicating 
strong predictive accuracy for this marker. On the other hand, a comparison of the LR- for 
each test did not show a statistically-significant difference among the different markers. 
Furthermore, we compared the AUC between the three tests (Figure 4) and found that 
PAMG-1 has the highest predictive accuracy for spontaneous preterm birth within 7 days of 
testing, with the phIGFBP-1 showing the lowest predictive accuracy: PAMG-1 0.961, fFN 
0.874, phIGFBP-1 0.801. 
 
When the bivariate model was fitted to each test separately for all available studies, the 
estimates of pooled sensitivities (SN) for PAMG-1, fFN and phIGFBP-1 for sPTB≤7d were 
73.5% (95% CI, 0.63-0.82), 75.3% (95% CI, 0.69-0.81), and 71.0% (95% CI, 0.61-0.80); 
pooled specificities (SP) were 96.6% (95% CI, 0.95-0.98), 83% (95% CI, 0.80-0.86), and 
80.2% (95% CI, 0.76-0.84); pooled positive likelihood ratios (LR+) were 21.69 (95% CI, 
14.38-32.72), 4.40 (95% CI, 3.76-5.14), and 3.58 (95% CI, 2.73-4.70); pooled negative 
likelihood ratios (LR–) were 0.27 (95% CI, 0.19-0.40), 0.30 (95% CI, 0.24-0.37), and 0.35 
(95% CI, 0.26-0.51). 
 
Discussion 
The results of our systematic review suggest that PAMG-1 has a strong predictive accuracy 
for sPTB≤7d in women with signs and symptoms of PTL. The reported PPV for PAMG-1 is 
a major improvement compared to phIGFBP-1 and fFN biomarker tests, which are used to 
rule out preterm labor, due to their high NPVs. The positivity rate of each biomarker 
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remained relatively consistent throughout the studies (7.9%, 23.0%, and 29.7% for PAMG-1, 
fFN, and phIGFBP-1, respectively). Given the potential of a positive biomarker test to 
influence the decision to admit and/or treat, a test with a lower positivity rate and higher PPV 
may lead to reductions in unnecessary hospitalizations and in-utero transfers to tertiary care 
centers and allow for more judicious use of therapeutic interventions, such as antenatal 
corticosteroids and tocolytic agents. 
 
The strength of this review stems from its rigorous methodology, which included stringent 
study selection criteria, recent literature searches, and a highly specific area of focus. 
Additionally, a modified version of the QUADAS-2 quality assessment was used to 
determine study quality. Contemporary statistical methods were used to obtain summary 
measures of the predictive accuracies.  
 
Our study has some important limitations. First, the study may be underpowered, as we 
weren’t able to attain convergence in the Low and Intermediate Risk groups. Therefore, the 
model had to be simplified to include random study effects only, without random effects for 
sensitivity and specificity by study. Additionally, the three risk groups showed a variation of 
sensitivity and specificity. These metrics shouldn’t dependent on the prevalence of the 
disease, as compared to predictive values. This heterogeneity could be due to within-study 
error and/or other population characteristics. The reason for variation across populations 
should be further investigated. Second, the three biomarkers didn’t have the same number of 
subjects. Furthermore, only 45% of studies were considered at low risk of bias. This included 
studies that didn’t specify their definition of PTB, and thus may have included medically-
indicated deliveries. This effect is expected to be minimal given that few studies fell into this 
group, and more than two-thirds of PTBs are spontaneous. Given the complexity and 
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heterogeneity of available studies, the performance endpoints were limited to sPTB≤7d, as 
not all studies included information for other endpoints, such as 48 hours or 14 days. 
 
Alternative analysis methods may produce different pooled estimates than found here. A 
simple pooled estimate may be obtained directly by summing numerators and denominators 
from the raw data across studies but has severe limitations as it assumes lack of heterogeneity 
across studies. Thus, random effects models are required to describe variability in test 
accuracy across studies, which in addition assumes independence of sensitivity and 
specificity. The bivariate mixed effects model of Reitsma, et. al. is a widely accepted method 
for meta-analysis of diagnostic tests as it overcomes the limitations of simple pooling by 
jointly modeling sensitivity and specificity.31,36 Apart from accounting for between study 
variability due to both random error and inherent differences in studies due to design, 
population, or study procedures, the bivariate mixed effects model method also allows for 
inclusion of covariates.33-37 
 
Lastly, our review didn’t look at the impact of test performance on patient management and 
resource economics. This is an area for future research. Additionally, the heterogeneity of 
each test’s performance using individual patient data (IPD) and meta-regression techniques 
looking at covariates such as gestational age, contraction frequency, and CL at presentation 
should be attempted. 
 
To the best of our knowledge, this is the first systematic review to compare performance of 
the PAMG-1, fFN and phIGFBP-1 biomarkers for prediction of sPTB across different risk 
classification groups. While Boots et al.94 discussed the effect of disease prevalence on test 
results, only the performance for a single pre-test probability (20%) was reported. As the pre-
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test probability of sPTB≤7d varied significantly among the publications (0.9%15-52%16), the 
predictive values for one population with a certain pre-test probability may not apply to 
another. The pre-test probabilities for sPTB≤7d can vary among populations due to country 
or center-specific algorithms for PTL diagnosis that call for biomarker test use only with 
equivocal diagnosis, such as CL between 15-30mm95 or those who present with any symptom 
of PTL and minimal cervical dilation.15 While our conclusions on the performance of fFN 
and phIGFBP-1 are consistent with those in previous systematic reviews,96,97 our work 
includes several studies published since then. Furthermore, our study reconfirms the effect of 
prevalence (or pre-test probability) on the performance of biomarker tests for the prediction 
of sPTB≤7d. 
 
Based on the probability of sPTB≤7d in patients with CL between 15-30mm reported in 
major publications, 28-30 the following clinical inferences may be drawn from our data: 
• For the regions or centers where the CL by transvaginal ultrasound are not routinely used 
(e.g. the U.S., U.K.), biomarker test performance for the prediction of sPTB≤7d would be 
commensurate with the performance reported for the Low Risk group (PPV 34.4%, 9.1%, 
6.1%, and NPV 98.9%, 99.0%, 98.5% for PAMG-1, fFN, and phIGFBP-1, respectively). 
• For the regions or centers where biomarker tests are only used in patients with a CL between 
15-30mm (e.g. Europe), biomarker test performance for the prediction of sPTB≤7d would be 
commensurate with the performance reported for the Intermediate Risk group (PPV 69.4%, 
28.8%, 25.4%, and NPV 97.6%, 97.2%, 96.1% for PAMG-1, fFN, and phIGFBP-1, 
respectively). 
• For the regions or centers where biomarker tests are only used in patients with a CL <15mm, 
biomarker test performance for the prediction of sPTB≤7d would be commensurate with the 
performance reported for the High-Risk group (PPV 82.9%, 50.3%, 53.7%, and NPV 92.4%, 
77.6%, 96.3% for PAMG-1, fFN, and phIGFBP-1, respectively). 
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We conclude that while all three biomarker tests had similarly high NPVs and LR-, the 
PAMG-1 test had the highest PPV and LR+ across all risk stratification groups (p<0.05). As 
such, our review supports the conclusions of the European Association of Perinatal Medicine 
(EAPM) guidelines, that the PAMG-1 test is the most accurate test to be used in women with 
a CL between 15-30mm.95
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Study Year Country(ies) N Study Design Inclusion Criteria 
Testing 
Gestation 
Week 
 
Biomarker 
Studied 
Reference Standard 
Low Risk Group 
Bartnicki et al.49  1996 USA 116 Prospective 
Symptoms of threatened preterm labor  
Minimal cervical dilatation (≤2 cm) 
Intact amniotic membranes 
22 - 35 weeks fFN PTB ≤7 Days 
Cooper et al.19 2012 Canada 349 Prospective 
Symptoms of threatened preterm labor  
Singleton or multiple gestation 
Clinically intact membranes 
24 - 32 weeks phIGFBP-1 PTB ≤7 Days, ≤14 Days, PTB <37 weeks 
Desjardins et al.53 2008 Canada 361 Retrospective Cohort 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Cervical dilation <3 cm  
22 - 34 weeks fFN PTB ≤7 Days, ≤14 Days, <35 weeks 
Gao et al.22 2014 China 124 Prospective 
Symptoms of threatened preterm labor  
Cervical dilatation ≤2 cm 
Intact membranes 
No other serious pregnancy complications and concurrent disorders such as 
hypertensive disorders, placenta previa, heart disease, chronic nephritis, viral 
hepatitis 
Singleton pregnancy 
20 - 34 weeks fFN 
 PTB ≤7 days, ≤14 
days, < 34 weeks, and 
< 37 weeks 
LaShay et al.55 2000 USA 118 Prospective cohort 
Symptoms of threatened preterm labor  
Intact amniotic membranes 
Cervical dilation <3 cm  
No prior history of coitus within the previous 24 hr, or a prior vaginal 
examination with lubricant, were also excluded 
22 - 34 weeks fFN PTB < 48 hrs, ≤7 Days, <37 weeks 
Melchor et al.40 2017 Spain 378 Retrospective cohort  
Symptoms of threatened preterm labor  
Clinically intact amniotic membranes as determined by speculum examination 
Minimal cervical dilatation (<3 cm) 
Singleton gestation 
Valid biochemical test 
Recorded digital examination result 
24 - 35 weeks PAMG-1, fFN 
sPTB ≤7 Days, ≤14 
Days  
Peaceman et al.52  1997 USA 725 Prospective 
Symptoms of threatened preterm labor  
Intact membranes 
No prior tocolysis 
Cervical dilation <3 cm 
Singleton gestation 
24 - 35 weeks fFN PTB ≤ 7 days, ≤14 days, < 37 weeks 
Ravi et al.43 2017 United Arab Emirates 72 
Prospective 
observational  
Symptoms of threatened preterm labor  
Clinically intact amniotic membranes as determined by speculum examination 
Singleton gestation 
Minimal cervical dilatation (≤3 cm) 
23 - 35 weeks PAMG-1 sPTB ≤7 Days, ≤14 Days  
Riboni et al.54  2011 Italy 210 Prospective Symptoms of threatened preterm labor  Clinically intact membranes 24 - 34 weeks 
fFN, 
phIGFBP-1 
PTB < 37 weeks, PTB 
<34 and <37 weeks 
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Singleton gestation 
Wing et al.15 2017 USA 635 Prospective observational 
Symptoms of threatened preterm labor  
Clinically intact amniotic membranes as determined by speculum examination 
Minimal cervical dilatation (<3 cm) 
24 - 35 weeks PAMG-1, fFN 
sPTB ≤7 Days, ≤14 
Days  
Intermediate Risk Group 
Altinkaya et al.83 2009 Turkey 105 Prospective 
Patients with and without symptoms of preterm labor (only patients with 
symptoms of preterm labor were included) 
Clinically intact membranes 
Singleton gestation 
22 - 34 weeks  phIGFBP-1 
PTB ≤7 Days, 
preterm birth <37 
weeks 
Azlin et al.82 
 
2010 
 
Malaysia 51 Prospective 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Singleton gestation 
Cervical dilations <3 cm 
24 - 36 weeks  phIGFBP-1 PTB ≤7 days 
Benattar et al.62 1997 France 124 Prospective Cohort 
Symptoms of threatened preterm labor  
>5 contractions per hour associated  
cervical changes since the last examination 
24 - 36 weeks fFN PTB ≤7 Days, <14 Days 
Bolotskikh et al.21 2017 Russia 99 Prospective Observational 
Symptoms of threatened preterm labor  
Contractions via CTG 
No clinical rupture of membranes (intact amniotic membranes upon vaginal 
exam) 
Singleton gestation 
Cephalic presentation 
22 - 37 weeks PAMG-1 sPTB ≤7 Days, ≤14 Days  
Brik et al.81 2010 Spain 276 Consecutive 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Singleton gestation 
24 - 34 weeks phIGFBP-1 
sPTB ≤48 hours, ≤7 
Days, sPTB <32 and 
<34 Weeks 
Closset et al.68 2001 France  61 Prospective Cohort 
Symptoms of threatened preterm labor  
Singleton gestation 
Patients with symptoms of threatened preterm labor 
24 - 36 weeks fFN PTB ≤7 Days 
Danti et al.79 2011 Italy 60 Consecutive 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Singleton gestations
24 - 32 weeks phIGFBP-1 PTB ≤7 Days, PTB <34 and <37 weeks 
Diaz et al.75 2009 Ecuador 180 Prospective Cohort 
Symptoms of threatened preterm labor  
Clinically intact membranes 
First time singleton gestation 
Cervical dilation <3 cm 
24 - 36 weeks fFN 
PTB ≤7 Days, ≤14 
Days, ≤21 Days, <35 
and <37 Weeks 
Eroglu et al.73 2007 Turkey 51 Prospective 
Patients with and without symptoms of preterm labor (only patients with 
symptoms of preterm labor were included) 
≥10 contractions per hr 
Clinically intact membranes 
Singleton gestation 
24 - 35 weeks phIGFBP-1 fFN 
PTB ≤7 Days, PTB 
<35 
Fatkullin et al.45 2016 Russia 45 Prospective Symptoms of threatened preterm labor  24 - 35 weeks PAMG-1 sPTB ≤7 Days, ≤14 
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
Observational Clinically intact membranes 
Minimal cervical dilation 
Cervical length ≤25 mm 
Days  
Foxman et al.58 2004 USA 139 Prospective Symptoms of threatened preterm labor  Singleton 22 - 34 weeks fFN PTB ≤7 Days 
Fuchs et al.80 2017 France 180 Prospective Cohort 
Symptoms of threatened preterm labor  
Singleton pregnancies 
Clinically intact membranes 
Cervical length < 25 mm 
24 - 34 weeks phIGFBP-1 
sPTB ≤7 Days, ≤14 
Days, <34 and <37 
weeks 
Giles et al.71 2000 Australia 150 Random Cohort  
Symptoms of threatened preterm labor  
Contractions ≥2 in 10 minutes 
Clinically intact membranes 
Excludes vaginal bleeding, a history of sexual intercourse or vaginal 
examination in the preceding 24 hours 
24 - 34 weeks fFN PTB ≤7 Days 
Gomez et al.74 2005 Chile 215 Prospective Cohort 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Cervical dilatation ≤3 cm  
Singleton gestation 
Uterine contractility of 3 in 30 minutes 
22 - 35 weeks fFN 
sPTB ≤48 hours, ≤7, 
≤14 Days, Delivery 
≤32 and ≤35 Weeks 
Groom et al.59 2006 New Zealand 179 Retrospective Cohort 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Cervical dilation ≤3 cm 
22 - 34 weeks fFN 
sPTB ≤7 Days, <34 
Weeks and <37 
Weeks 
Hadzi-Lega et 
al.48 2017 Macedonia 57 
Prospective 
observational  
Symptoms of threatened preterm labor  
Clinically intact membranes 
Singleton gestation 
Cervical dilation ≤3 cm 
20 - 35 weeks PAMG-1 sPTB ≤7 Days, ≤14 Days  
Henrich et al.60 2010 Germany 81 Prospective Cohort 
Symptoms of threatened preterm labor  
Regular uterine contractions 
Singleton gestation 
22 - 33 weeks fFN 
PTB ≤7 Days, ≤14 
Days, <35 Weeks, 
<38 Weeks 
Heverhagen et 
al.17 2015 Switzerland 64 
Prospective 
observational  
Symptoms of threatened preterm labor  
Clinically intact membranes 
Singleton gestation
24 - 37 weeks PAMG-1 sPTB ≤7 Days, ≤14 Days  
Iams et al.14  1995 USA & Canada 192 
Prospective 
Cohort 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Cervical dilation < 3cm 
24 - 34 weeks fFN sPTB ≤7 Days, <14 Days, <21 Days 
Konoplyannikov 
et al.47 2016 Russia 71 
Prospective 
observational  
Symptoms of threatened preterm labor  
Clinically intact membranes 
Singleton gestation 
Cervical dilation <3 cm 
20 - 37 weeks PAMG-1 sPTB ≤7 Days, ≤14 Days  
Liong et al.66 2015 Australia 64 Retrospective Cohort 
Symptoms of threatened preterm labor  
Intact membranes 
Singleton gestation 
22 - 36 weeks fFN sPTB ≤7 Days 
Lopez et al.70 2000 USA 85 Retrospective Symptoms of threatened preterm labor  24 - 35 weeks fFN sPTB ≤7 Days 
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Cohort Clinically intact membranes 
Cervical dilation ≤3 cm 
Singleton gestation 
Lotfi et al.44 2015 United Arab Emirates 151 
Prospective 
observational  
Symptoms of threatened preterm labor  
Clinically intact membranes 
Cervical dilatation ≤3 cm 
Singleton gestation 
20 - 37 weeks PAMG-1 sPTB ≤7 Days, ≤14 Days  
Lou et al.46 2016 United Kingdom 65 
Prospective 
observational 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Singleton gestation 
Cervical dilatation <4 cm 
24 - 35 weeks PAMG-1 sPTB ≤7 Days, ≤14 Days  
Lowe et al.63 2004 USA 41 Prospective 
Symptoms of threatened preterm labor  
Uterine contractions and/or cervical change  
Women who were transferred already receiving tocolytic medications 
Maternal age >16 years 
Cervical dilation ≤3 cm for primigravid women and ≤4 cm for multiparous 
women 
23 - 34 weeks fFN PTB ≤7 Days 
Luzzi et al.58  2003 USA 133 Prospective 
Symptoms of threatened preterm labor  
Intact membranes 
Cervical dilation <3 cm 
24 - 35 weeks fFN sPTB ≤7 Days 
MacDonald et 
al.50  2007 Canada 38 
Retrospective 
Cohort 
Patients with symptoms of preterm labor, including abdominal pain, back pain, 
abdominal cramps, lower abdominal pelvic pressure 24 - 35 weeks fFN PTB ≤7 Days 
Malak et al.65 1996 United Kingdom 112 
Prospective 
Cohort 
Symptoms of threatened preterm labor  
Clinically intact membranes  
Cervical dilation < 2 cm 
Singleton gestation 
24 - 37 weeks fFN PTB ≤7 Days 
McKenna et al.72 1999 USA 54 Prospective Cohort 
Symptoms of threatened preterm labor  
  22 - 34 weeks  fFN 
PTB <7 Days, <15 
Days 
Nikolova et al.33 2016 
Finland; 
Macedonia; 
Russia 
328 Prospective observational 
Symptoms of threatened preterm labor  
Intact members 
Cervical dilation ≤3 cm 
Singleton gestation 
≥ 18 years old 
20 - 37 weeks PAMG-1, phIGFBP-1 
sPTB ≤7 Days, ≤14 
Days  
Sakai et al.51  2003 Japan 116 Retrospective 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Regular uterine contractions of >6 per hour by CTG 
Effacement >50% 
Cervical dilation >2 cm 
Singleton gestation
<37 weeks fFN PTB ≤7 Days, 
Skoll et al.69 2006 Canada 149 Prospective Cohort 
Symptoms of threatened preterm labor  
Clinically intact membranes 
No moderate or severe bleeding 
No indication for preterm delivery
24 - 34 weeks  fFN PTB ≤7 Days, <34 weeks 
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Sümer et al.64 2010 Turkey 67 Prospective Cohort 
Symptoms of threatened preterm labor  
Intact membranes 
Singleton gestation 
26 - 36 weeks fFN PTB ≤7 Days 
Swamy et al.59 2005 USA 404 Prospective Cohort 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Last digital examination and sexual intercourse >24 hours 
Cervix <2cm dilated and >1cm long 
22 - 34 weeks fFN PTB ≤7 Days 
Tekesin et al.61 2005 Germany 170 Prospective Cohort 
Symptoms of threatened preterm labor  
Intact membranes  
≥4 contractions in 20 mins on CTG or >8 contractions per hour 
Cervical effacement >50%  
Dilatation >2 cm 
Singleton gestation  
24 - 34 weeks fFN sPTB ≤7 Days, <14 Days, <21 Days 
Tsoi et al.67 2006 South Africa 195 Prospective Cohort 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Cervical dilation <3 cm 
Singleton gestation 
24 - 36 weeks fFN PTB ≤7 Days 
Van Baaren et 
al.29 2014 Netherlands 665 
Prospective 
observational 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Cervical dilation <3 cm 
24 - 34 weeks  fFN sPTB ≤7 Days 
Van Holsbeke et 
al.41 2016 Belgium 49 
Prospective 
observational  
Symptoms of threatened preterm labor  
Clinically intact membranes 
Cervical dilation <3 cm 
Cervical length <30 mm  
22 - 34 weeks PAMG-1, fFN 
sPTB ≤7 Days, ≤14 
Days  
High Risk Group 
Abo Ek-Ezz et 
al.89 2014 Kuwait 57 Prospective 
Symptoms of preterm labor 
Clinically intact membranes 
Singleton gestation 
24 - 34 weeks  phIGFBP-1 PTB ≤7 days 
Bruijn et al.28 2016 Netherlands 350 Prospective 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Singleton gestation 
Cervical length <30 mm 
24 – 34 weeks fFN, phIGFBP-1 sPTB ≤7 Days 
Çekmez et al.20 2017 Turkey 72 Prospective Observational 
Symptoms of threatened preterm labor  
≥4 contractions in 60 mins on CTG 
Cervical dilation of >1 cm to <3 cm 
Effacement of >50% 
Cervical length of <30 mm  
Singleton pregnancy  
24 - 34 weeks PAMG-1, fFN PTB ≤7 Days 
Cheung et al.77 2013 China 22 Prospective Cohort 
Symptoms of preterm labor 
≥ 18 years old  24 - 34 weeks fFN 
PTB ≤24 Hours, ≤48 
Hours, ≤7 Days, ≤14 
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> 6 contractions per hour on CTG  
Cervical dilatation of ≤3 cm 
Days, <34 weeks and 
<37 weeks 
Kwek et al.89 2004 Singapore 42 Prospective 
Symptoms of preterm labor 
≥1 uterine contractions in 10 min 
Clinically intact membranes
23 – 33 weeks phIGFBP-1 
PTB ≤48 hours, ≤7 
Days, PTB <34 and 
<36 weeks 
Lembet et al.91 2002 Turkey 36 Prospective 
Symptoms of preterm labor 
Clinically intact membranes 
Singleton gestation 
20 - 36 weeks phIGFBP-1 PTB ≤48 hours, ≤7 Days, PTB <37 weeks 
Magro-Malosso 
et al.78 2016 Italy 43 
Retrospective 
Cohort 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Singleton gestation 
Cervical length ≤20 mm 
22 – 34 weeks  fFN 
sPTB ≤48 Hours, ≤7 
Days, ≤14 Days, ≤21 
Days 
Nikolova et al.42 2015 Macedonia; Russia 203 
Prospective 
observational 
Symptoms of threatened preterm labor  
Clinically intact amniotic membranes  
Minimal cervical dilatation (≤3 cm) 
Singleton gestation 
20 - 37 weeks PAMG-1, fFN 
sPTB ≤7 Days, ≤14 
Days  
Park et al.87 2003 Korea 50 Not Reported 
Patients with symptoms of preterm labor requiring admission 
Singleton gestation 
No parturition 24 – 48 hours after admission 
24 - 34 weeks  phIGFBP-1 
PTB ≤7 Days, PTB 
<34 and <37 weeks 
Sanchez Martinez 
et al.85 2006 Spain 149 Prospective 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Cervical dilation <3 cm 
24 - 35 weeks phIGFBP-1 sPTB ≤7 Days, sPTB <36 weeks 
Senden et al.76 1996 United Kingdom 29 Prospective 
Symptoms of threatened preterm labor  
Singleton gestation 
Cervical dilations <4 cm 
25 - 35 weeks fFN PTB ≤7 Days 
Singh et al.16 2013 India 50 Prospective 
Symptoms of preterm labor 
Clinically intact membranes 
Cervical dilation of 1 to <3 cm 
28 - 36 weeks phIGFBP-1 
PTB ≤48 hours, ≤7 
Days, PTB <34 and 
<36 weeks 
Sunagawa et al.88 2008 Japan 76 Retrospective 
Symptoms of preterm labor 
Clinically intact membranes 
Singleton gestation 
22 - 34 weeks phIGFBP-1 PTB ≤72 hours, PTB ≤7 days 
Tanir et al.86 2009 Turkey 68 Prospective 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Cervical dilation <3 cm 
Singleton gestation 
24 – 36 weeks phIGFBP-1 PTB ≤72 hours, PTB ≤7 days 
Ting et al.84 2007 Singapore 94 Prospective 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Singleton gestation 
24 - 34 weeks phIGFBP-1 PTB ≤48 hours, ≤7 Days, ≤14 Days 
Tripathi et al.18 2016 India 468 Prospective Observational 
Symptoms of threatened preterm labor  
Clinically intact membranes 
Singleton gestation 
28 - 36 weeks fFN,  phIGFBP-1 
PTB ≤7 Days, <34 
Weeks, <37 Weeks 
Winograd et al.90 2003 Argentina 85 Not Reported Symptoms of preterm labor Clinically intact membranes 24 - 35 weeks phIGFBP-1 sPTB ≤7 days 
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sPTB, spontaneous preterm birth; CTG, cardiotocography   
Singleton gestation 
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Table 2. The summary estimates for the Sensitivity and Specificity for preterm birth 
within 7 days of the three biomarker tests†  
Biomarker test N 
 Sensitivity (95% 
CI) 
Specificity (95% CI) 
 Low Risk Group 
PAMG-1 1074  0.53 (0.29-0.76) 0.98 (0.96-0.99) 
fFN 2667  0.65 (0.50-0.77) 0.85 (0.80-0.88) 
phIGFBP-1 559  0.48 (0.23-0.74) 0.83 (0.75-0.88) 
 Intermediate Risk Group 
PAMG-1 929  0.77 (0.64-0.86) 0.97 (0.94-0.98) 
fFN 3714  0.77 (0.71-0.82) 0.81 (0.77-0.84) 
phIGFBP-1 1108  0.68 (0.55-0.78) 0.80 (0.73-0.86) 
 High Risk Group 
PAMG-1 275  0.78 (0.17-0.98) 0.94 (0.81-0.98) 
fFN 1050  0.25 (0.10-0.50) 0.91 (0.84-0.95) 
phIGFBP-1 1525  0.92 (0.81-0.97) 0.72 (0.60-0.81) 
 All 
PAMG-1 2278  0.76 (0.57-0.89) 0.97 (0.95-0.98) 
fFN 7431  0.58 (0.47-0.68) 0.84 (0.81-0.87) 
phIGFBP-1 3192  0.93 (0.88-0.96) 0.76 (0.70-0.80) 
†Pooled estimates were obtained for each risk classification group using a bivariate linear 
mixed model for the logit of sensitivity and specificity, with each diagnostic test as a 
covariate. CI, confidence interval; fFN, fetal fibronectin; phIGFBP-1, phosphorylated 
insulin-like growth factor-binding protein-1; PAMG-1, placental alpha-microglobulin-1 
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Table 3. The summary estimates for the prediction of preterm birth within 7 days of the 
three biomarker tests† 
Biomarker 
test 
PPV (95% CI) NPV (95% CI) LR+ (95% CI) LR- (95% CI) 
Low Risk Group (weighted average pretest probability 0.023 or CL >30 mm) 
PAMG-1 0.34* (0.14-0.55) 0.99 (0.98-0.99) 22.27* (8.87-55.91) 0.48 (0.28-0.82) 
fFN 0.09 (0.06-0.12) 0.99 (0.99-0.99) 4.23 (2.84-6.29) 0.42 (0.28-0.63) 
phIGFBP-1 0.06 (0.01-0.11) 0.99 (0.98-0.99) 2.76 (1.23-6.18) 0.63 (0.35-1.12) 
Intermediate Risk Group (weighted average pretest probability 0.091 or CL 15-30 mm) 
PAMG-1 0.69* (0.59-0.80) 0.98 (0.97-0.99) 22.63* (13.99-36.61) 0.24 (0.15-0.38) 
fFN 0.29 (0.25-0.32) 0.97 (0.97-0.98) 4.04 (3.42-4.77) 0.28 (0.22-0.36) 
phIGFBP-1 0.25 (0.20-0.31) 0.96 (0.95-0.97) 3.39 (2.54-4.54) 0.40 (0.29-0.56) 
High Risk Group (weighted average pretest probability 0.261 or CL <15 mm) 
PAMG-1 0.83* (0.67-0.98) 0.92 (0.77-1.00) 13.72* (4.59-41.00) 0.23 (0.03-2.12) 
fFN 0.50 (0.29-0.72) 0.78 (0.73-0.82) 2.87 (1.22-6.76) 0.82 (0.63-1.06) 
phIGFBP-1 0.54 (0.45-0.62) 0.96 (0.93-1.00) 3.28 (2.33-4.64) 0.11 (0.04-0.27) 
All 
PAMG-1 0.76* (0.69-0.84) 0.97 (0.94-0.99) 22.51* (15.09-33.60) 0.24 (0.12-0.48) 
fFN 0.34 (0.29-0.39) 0.93 (0.92-0.95) 3.63 (2.93-4.50) 0.50 (0.39-0.64) 
phIGFBP-1 0.35 (0.31-0.40) 0.99 (0.98-0.99) 3.80 (3.11-4.66) 0.09 (0.05-0.16) 
†Pooled estimates were obtained for each risk classification group using a bivariate linear 
mixed model for the logit of sensitivity and specificity, with each diagnostic test as a 
covariate. CI, confidence interval; PPV, positive predictive value; NPV, negative predictive 
value; LR, likelihood ratio; CL, cervical length, PAMG-1, placental alpha-microglobulin-1; 
fFN, fetal fibronectin; phIGFBP-1, phosphorylated insulin-like growth factor-binding protein-
1; *statistical superiority based on a two-sided pairwise comparison with p<0.05  
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2. Methodological quality of studies included in the meta-analysis  
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